CIBC Bancorp USA’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$361K Buy
9,705
+4,282
+79% +$254K ﹤0.01% 1570
2026
Q2
$327K Buy
5,423
+1,074
+25% +$59.6K ﹤0.01% 1493
2026
Q1
$253K Buy
+4,349
New +$200K ﹤0.01% 1494
2025
Q3
$325K Buy
+8,100
New +$285K ﹤0.01% 1047

Other funds holding XENE

CIBC Bancorp USA's XENE Position: Q3 2026 in Review

CIBC Bancorp USA increased its Xenon Pharmaceuticals (XENE) stake by 79% in Q3 2026, buying an estimated $254K and bringing the position to 9,705 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

CIBC Bancorp USA first reported a position in XENE in Q3 2025 and has held it in 4 quarters since. 284 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • CIBC Bancorp USA held 9,705 shares of Xenon Pharmaceuticals worth $361K as of Q3 2026.
  • CIBC Bancorp USA bought 4,282 Xenon Pharmaceuticals shares in Q3 2026, an estimated $254K.
  • Xenon Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1570 holding.
  • CIBC Bancorp USA first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 284 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.